Development of a novel catalytic array

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$263,772.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43RR024807-01
Award Id:
85992
Agency Tracking Number:
RR024807
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
LIFESENSORS, INC., 271 GREAT VALLEY PKY, MALVERN, PA, 19355
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
060013641
Principal Investigator:
JOSEPH MANIMALA
(610) 644-8845
MANIMALA@LIFESENSORS.COM
Business Contact:
VARSHA LUTHRA
() -
butt@lifesensors.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Bioinformatics tools will be generated for a class of ~ 100 proteins known as de- ubiquitinating enzymes (DUBs), which play an important role in cell survival, proliferation, and differentiation. LifeSensor's proprietar y SUMO expression enhancement technology permits expression and purification of DUBs with relative ease, and a high throughput microarray of these proteins will afford rapid and cost effective screening. Thus, it is proposed to develop a DUB microarray for the purpose of basic research, biomarker discovery, diagnostics/prognostics, and therapeutics. The DUB microarray will have obvious utility in biomarker discovery and diagnostics development. Expression of DUBs has been associated with diseases such as ca ncer, diabetes, and Parkinsonism. Over- or under-expression of proteins in disease states tend to elicit elevated or diminished auto-antibody production against those proteins. Thus, auto-antibody profiling can assist in identifying the type and stage of a disease. When a biomarker is identified, it can be further studied for its role in the diagnosis and prognosis of the disease. The particular biomarker could also be a therapeutic target. A DUB microarry not only allows one to perform high throughput scre ening of samples, but also to evaluate expression levels of DUBs in samples under identical conditions to correlate their effect on each other's expression levels under different circumstances. In the first aim, 10 (ten) DUBs will be immobilized on a varie ty of solid supports to determine the optimum support in terms of retention of enzyme activity. Next, the catalytic function of the retained DUBs will be compared with their function in a standard assay system. Finally, 50 (fifty) serum samples from the ge neral population will be profiled for variation in the expression of autoantibodies against the DUBs. In Phase II, arrays will be built consisting of all known DUBS for ubiquitin and relevant ubiquitin-like proteins.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government